Is Ado-Trastuzumab Emtansine Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Ado-Trastuzumab Emtansine? Is Ado-Trastuzumab Emtansine safe for nursing mother and child? Does Ado-Trastuzumab Emtansine extracts into breast milk? Does Ado-Trastuzumab Emtansine has any long term or short term side effects on infants? Can Ado-Trastuzumab Emtansine influence milk supply or can Ado-Trastuzumab Emtansine decrease milk supply in lactating mothers?

• DrLact safety Score for Ado-Trastuzumab Emtansine is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Ado-Trastuzumab Emtansine may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Ado-Trastuzumab Emtansine may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Ado-Trastuzumab Emtansine .
• It is recommended to evaluate the advantage of not breastfeeding while using Ado-Trastuzumab Emtansine Vs not using Ado-Trastuzumab Emtansine And continue breastfeeding.
• While using Ado-Trastuzumab Emtansine Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Anticuerpo monoclonal recombinante inmunoglobulina G1 dirigido contra la proteína producida por el gen HER2 (receptor 2 de factor de crecimiento epidérmico humano) sobreexpresado en 25 a 30% de cánceres de pecho. A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna. Su elevado peso molecular y su naturaleza protéica hacen prácticamente imposible tanto el paso a leche como la absorción intestinal por parte del lactante: Su baja biodisponibilidad oral dificulta el paso a plasma del lactante a partir de la leche materna ingerida, salvo en prematuros y periodo neonatal inmediato, en los que puede haber mayor permeabilidad intestinal. Aunque posiblemente seguro durante la lactancia, su muy larga semivida de eliminación (18 a 28,5 días) y sus posibles efectos secundarios hacen que hasta conocer más datos publicados sobre este fármaco pueda ser prudente no amamantar. El periodo de "lavado" (tiempo que tarda el medicamento en eliminarse por completo del organismo) a esperar a amamantar serían 143 días (5 vidas medias) tras la última dosis. A tener en cuenta que la vida media de Trastuzumab emtansina es mucho más corta, de tan sólo unos 4 días.

No information is available on the clinical use of ado-trastuzumab during breastfeeding. Because trastuzumab is a large protein molecule with a molecular weight of 145,531, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, ado-trastuzumab emtansine also contains the small molecule cytotoxin, DM1, the manufacturer recommends avoiding breastfeeding during and for 7 months following ado-trastuzumab emtansine therapy.